Advancing Oncology Trials with Global Expertise

Bringing an oncology drug to market requires more than scientific innovation—it demands seamless coordination, global capabilities, and deep operational expertise across early clinical phases. For one European sponsor developing a promising ADC therapy for advanced solid tumors, navigating a U.S.-based Phase I/II trial posed significant logistical and regulatory hurdles.

That’s where TFS HealthScience stepped in.

In this case study, you’ll learn how TFS supported study start-up, clinical monitoring, and site management across continents—ensuring high-quality data, rapid enrollment, and inspection-ready trial documentation.

Download the Case Study to Learn:

• How to manage early-phase oncology trials across regions
  See how TFS established dual-region project teams for real-time communication and local site execution in the U.S., while maintaining cost efficiency from Europe.
• Strategies to accelerate patient enrollment
  Learn how pre-identification of patients and streamlined slot assignment processes boosted enrollment rates at U.S. sites.
• The importance of responsive, inspection-ready site support
  Explore how TFS ensured continuous data quality, timely monitoring visits, and reliable TMF submission across a 24-month timeline.
• Key takeaways for scaling future Phase III oncology trials
  Discover operational practices that lay the groundwork for success in larger, later-phase studies.

If you’re a sponsor planning a Phase III oncology trial or managing early-phase studies in global markets, this case study provides a real-world example of how experienced CRO support can optimize trial execution and set the stage for long-term clinical success.

Learn more about our related services and resources:

TFS Oncology & Hematology